Literature DB >> 9635830

p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking.

Y Takagi1, H Osada, T Kuroishi, T Mitsudomi, M Kondo, T Niimi, S Saji, A F Gazdar, T Takahashi, J D Minna, T Takahashi.   

Abstract

Accumulating evidence suggests that the p53 gene is a good target for molecular epidemiological studies. We previously reported an association between the presence of p53 mutations and lifetime cigarette consumption. Although over 675 p53 mutations have been reported in lung cancers in the literature thus far, very little is known about the nature of such changes in lung cancers in the absence of a smoking background. In the present study, we therefore analysed 69 non-small-cell lung cancer specimens from individuals without any history of active smoking and identified p53 mutations in 26% of the cases. Statistical analysis of the present cohort of non-smokers also showed absence of significant relationship between p53 mutations and age, sex, histological type or disease stage. Comparison of mutational spectra between the present results in non-smokers and previously reported mutations in smokers clearly demonstrated G:C to T:A transversions to be significantly less frequent in non-smokers than in smokers (OR 5.35, 95% CI 1.77-16.12). Interestingly, G:C to C:G and G:C to A:T mutations were also observed in tumours of non-smokers at similar frequencies to G:C to T:A mutations, suggesting that these mutations can occur relatively frequently in the absence of active smoking. This study is, to our knowledge, the largest so far analysing a well-defined cohort of non-smokers in a single laboratory.

Entities:  

Mesh:

Year:  1998        PMID: 9635830      PMCID: PMC2150056          DOI: 10.1038/bjc.1998.258

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer.

Authors:  S L Naylor; B E Johnson; J D Minna; A Y Sakaguchi
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

Review 2.  Superoxide radical: an endogenous toxicant.

Authors:  I Fridovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  1983       Impact factor: 13.820

3.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

Authors:  S Rodenhuis; M L van de Wetering; W J Mooi; S G Evers; N van Zandwijk; J L Bos
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

4.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

5.  Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States?

Authors:  D R Shopland; H J Eyre; T F Pechacek
Journal:  J Natl Cancer Inst       Date:  1991-08-21       Impact factor: 13.506

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

7.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

8.  Effects of environmental tobacco smoke on urinary cotinine excretion in nonsmokers. Evidence for passive smoking.

Authors:  S Matsukura; T Taminato; N Kitano; Y Seino; H Hamada; M Uchihashi; H Nakajima; Y Hirata
Journal:  N Engl J Med       Date:  1984-09-27       Impact factor: 91.245

9.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

10.  Comparison of lung cancer incidence rates by histological type in high and low incidence countries, with reference to the limited role of smoking.

Authors:  A Hanai; T Benn; I Fujimoto; C S Muir
Journal:  Jpn J Cancer Res       Date:  1988-04
View more
  11 in total

1.  Human lung cancer and p53: the interplay between mutagenesis and selection.

Authors:  S N Rodin; A S Rodin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression.

Authors:  Sharad S Singhal; James Figarola; Jyotsana Singhal; Lokesh Nagaprashantha; David Berz; Samuel Rahbar; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

Review 3.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

Review 4.  Molecular biology of lung cancer.

Authors:  Wendy A Cooper; David C L Lam; Sandra A O'Toole; John D Minna
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 5.  TP53 mutations in nonsmall cell lung cancer.

Authors:  Akira Mogi; Hiroyuki Kuwano
Journal:  J Biomed Biotechnol       Date:  2011-01-18

6.  Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.

Authors:  Johanna Samulin Erdem; Vidar Skaug; Per Bakke; Amund Gulsvik; Aage Haugen; Shanbeh Zienolddiny
Journal:  BMC Cancer       Date:  2016-01-19       Impact factor: 4.430

Review 7.  Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.

Authors:  Guangbo Liu; Fen Pei; Fengqing Yang; Lingxiao Li; Amit Dipak Amin; Songnian Liu; J Ross Buchan; William C Cho
Journal:  Int J Mol Sci       Date:  2017-02-10       Impact factor: 5.923

8.  Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.

Authors:  Peng Song; Fanshuang Zhang; Yan Li; Guangjian Yang; Wenbin Li; Jianming Ying; Shugeng Gao
Journal:  Cancer Med       Date:  2019-03-07       Impact factor: 4.452

9.  Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

Authors:  S Zienolddiny; D Ryberg; M O Arab; V Skaug; A Haugen
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

10.  Synchronous neuroendocrine tumor and non-small-cell lung cancer in neurofibromatosis type 1.

Authors:  Andrew Hsu; Samuel Han
Journal:  Clin Case Rep       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.